Related Experiment Video
Updated: Feb 17, 2026
09:26
A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
Published on: March 23, 2016
20.7K
Ginkgo biloba and its potential role in glaucoma
1Department of Ophthalmology, University of California, San Francisco, San Francisco, California, USA.
Current Opinion in Ophthalmology
|December 6, 2017
Summary
Ginkgo biloba extract (GBE) may improve ocular blood flow in glaucoma patients. However, current research is limited and does not conclusively show benefits for visual field outcomes in glaucoma.
Area of Science:
- Ophthalmology
- Pharmacology
- Natural Products
Background:
- Glaucoma is a progressive optic neuropathy characterized by vision loss.
- Ginkgo biloba extract (GBE) possesses antioxidant and vascular properties.
- GBE is explored for its potential therapeutic effects in glaucoma management.
Purpose of the Study:
- To review existing research on the effects of Ginkgo biloba extract (GBE) in patients diagnosed with glaucoma.
- To evaluate the impact of GBE on ocular hemodynamics and visual field outcomes.
Main Methods:
- Systematic review of published studies.
- Analysis of research investigating GBE administration in glaucoma patients.
- Assessment of reported changes in ocular blood flow and visual field data.
Main Results:
- GBE administration is associated with increased ocular blood flow in glaucoma patients.
- Data regarding the effect of GBE on visual field outcomes remain inconclusive.
- Limited published data exist, highlighting the need for further investigation.
Conclusions:
- Ginkgo biloba extract demonstrates potential therapeutic benefits for glaucoma due to its antioxidant and vascular effects.
- While GBE may enhance ocular blood flow, conclusive evidence on its efficacy for improving clinical outcomes like visual field performance in glaucoma is currently lacking.
- Further rigorous clinical trials are warranted to establish the definitive role of GBE in glaucoma treatment.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
01:25Glaucoma: Overview
1.4K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.4K
01:28Angle Closure Glaucoma: Treatment
1.4K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.4K
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
719
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
719
01:28Nitric Oxide Signaling Pathway
6.4K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
6.4K